Since there is no abstract we provide the first sentence
In a recent issue of Annals of Surgical Oncology Heemskerk-Getherritsen et al. [1] provide clinical useful data supporting the efficacy of genetic testing and prophylactic mastectomy (PM) in unaffected and affected by breast cancer carriers of mutations in BRCA1 and BRCA2. No breast cancer occurred among 358 BRCA carriers (unaffected women, n = 177; affected, n = 181) after PM in a median follow-up of 4.5 years. However, is it PM the optimum preventive intervention, at the same time as data on other preventive options including prophylactic salpingo-oophorectomy (PBSO) chemoprevention and intensified surveillance have become available?
